Targeting α‐Synuclein: A Further Viewpoint
Sign Up to like & getrecommendations! Published in 2023 at "Movement Disorders"
DOI: 10.1002/mds.29345
Abstract: I was interested to read two distinctly different Viewpoint assessments of the recent publications describing the failure of first two anti-α-synuclein (AS) monoclonal antibody trials in Parkinson’s disease (PD) to demonstrate clinical efficacy on their… read more here.
Keywords: cell; function; disease; viewpoint ... See more keywords